The estimated Net Worth of Marion Dorsch is at least $4.95 Milion dollars as of 22 February 2021. Marion Dorsch owns over 7,578 units of Blueprint Medicines Corp stock worth over $1,975,992 and over the last 8 years he sold BPMC stock worth over $91,590. In addition, he makes $2,882,290 as Chief Scientific Officer at Blueprint Medicines Corp.
Sign up
Marion Dorsch BPMC stock SEC Form 4 insiders trading
Marion has made over 14 trades of the Blueprint Medicines Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 7,578 units of BPMC stock worth $281,220 on 22 February 2021.
The largest trade he's ever made was exercising 18,334 units of Blueprint Medicines Corp stock on 21 November 2017 worth over $680,375. On average, Marion trades about 3,963 units every 66 days since 2016. As of 22 February 2021 he still owns at least 22,828 units of Blueprint Medicines Corp stock.
You can see the complete history of Marion Dorsch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marion Dorsch biography
Dr. Marion Dorsch Ph.D. serves as Chief Scientific Officer of the Company. Dr. Dorsch has served as our chief scientific officer since November 2016. Prior to joining us, from April 2012 to November 2016, Dr. Dorsch served as Vice President of Biology at Agios Pharmaceuticals, Inc., or Agios. In this role, she was responsible for novel target validation, drug discovery, and biomarker strategy across Agios’ cancer, rare genetic diseases and immuno-oncology portfolios. During her tenure at Agios, Dr. Dorsch contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials. Prior to joining Agios, Dr. Dorsch was the Director of Cancer Biology at Sanofi Oncology, where she oversaw drug discovery efforts. Earlier in her career, Dr. Dorsch served as research project leader for sonidegib (Odomzo®), now approved in the United States and European Union for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and also worked in Inflammation Discovery at Millennium Pharmaceuticals, Inc. Dr. Dorsch received her Ph.D. in Tumor Immunology from the Free University of Berlin, Germany and was a postdoctoral fellow at Columbia University in New York.
What is the salary of Marion Dorsch?
As the Chief Scientific Officer of Blueprint Medicines Corp, the total compensation of Marion Dorsch at Blueprint Medicines Corp is $2,882,290. There are 5 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
How old is Marion Dorsch?
Marion Dorsch is 54, he's been the Chief Scientific Officer of Blueprint Medicines Corp since 2016. There are 10 older and 19 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
What's Marion Dorsch's mailing address?
Marion's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Blueprint Medicines Corp
Over the last 9 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr a Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
What does Blueprint Medicines Corp do?
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
What does Blueprint Medicines Corp's logo look like?
Complete history of Marion Dorsch stock trades at Blueprint Medicines Corp
Blueprint Medicines Corp executives and stock owners
Blueprint Medicines Corp executives and other stock owners filed with the SEC include:
-
Jeffrey Albers,
Chief Executive Officer, Director -
Christina Rossi,
Chief Commercial Officer -
Christopher Murray,
Senior Vice President, Technical Operations -
Kathryn Haviland,
Chief Operating Officer -
Tracey McCain,
Chief Legal Officer, Chief Compliance Officer -
Marion Dorsch,
Chief Scientific Officer -
Anthony Boral,
Chief Medical Officer -
Michael Landsittel,
Chief Financial Officer -
Jeffrey W. Albers J.D., M.B.A., MBA,
Chairman, CEO & Pres -
Jeffrey W. Albers M.B.A., J.D., MBA,
CEO, Pres & Director -
Kathryn Haviland,
Chief Operating Officer -
Tracey L. McCain Esq.,
Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. -
Dr. Fouad Namouni M.D.,
Pres of R&D -
Tracey L. Mccain,
Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. -
Michael Landsittel,
CFO & Treasurer -
Daniel Lynch,
Independent Chairman of the Board -
Nicholas Lydon,
Independent Director -
Charles Rowland,
Independent Director -
George Demetri,
Independent Director -
Lonnel Coats,
Independent Director -
Lynn Seely,
Independent Director -
Mark Goldberg,
Independent Director -
Alexis Borisy,
Director -
Alexis A. Borisy A.M.,
Co-Founder & Director -
Fouad Namouni,
President, Research & Development -
Debra Durso-Bumpus,
Chief Human Resource Officer -
Kristin Hodous,
IR Contact Officer -
Ariel Hurley,
Vice President - Finance, Controller -
Dr. Percy H. Carter M.B.A., Ph.D.,
Chief Scientific Officer -
Dr. Christopher K. Murray,
Sr. VP of Technical Operations -
Ariel Hurley,
Principal Accounting Officer, VP of Fin. & Controller -
Debra Durso-Bumpus,
Chief People Officer -
Dr. Fouad Namouni,
Pres of R&D -
Mark J Levin,
10% owner -
Rock Ventures Ii, L.P.Third...,
-
Kevin P Starr,
10% owner -
Habib J Dable,
-
John Tsai,
-
Daniella Beckman,
-
Christoph Lengauer,
Chief Scientific Officer -
L. Becker Hewes,
CHIEF MEDICAL OFFICER -
Percy H. Carter,
CHIEF SCIENTIFIC OFFICER -
Therapeutics, Inc. Tango,
Director -
Kate Haviland,
CHIEF EXECUTIVE OFFICER -
Philina Lee,
CHIEF COMMERCIAL OFFICER